129 related articles for article (PubMed ID: 31726478)
1. IgGκ light and heavy chain amyloidosis secondary to a B-cell lymphoproliferative disorder, whole picture on a renal biopsy.
Ville S; Kandel C; Delaunay J; Cantarovich D
Nephrology (Carlton); 2020 May; 25(5):429-430. PubMed ID: 31726478
[No Abstract] [Full Text] [Related]
2. Heavy and light chain (AHL)-type cardiac amyloidosis: first histopathologic-proven case illustrating involvement of the heart.
Sekulic M; Pichler Sekulic S; Weins A
Virchows Arch; 2020 Nov; 477(5):733-738. PubMed ID: 32388718
[TBL] [Abstract][Full Text] [Related]
3. AL amyloidosis with a localized B cell neoplasia.
Stuhlmann-Laeisz C; Schönland SO; Hegenbart U; Oschlies I; Baumgart JV; Krüger S; Röcken C
Virchows Arch; 2019 Mar; 474(3):353-363. PubMed ID: 30680453
[TBL] [Abstract][Full Text] [Related]
4. Splenic marginal zone lymphoma with a de novo t(8;14)(q24;q32) and a prolymphocytoid evolution responsive to rituximab-bendamustine.
Scapinello G; Pizzi M; Vio S; Nabergoj M; Visentin A; Martines A; Bonaldi L; Trentin L; Semenzato G; Piazza F
Ann Hematol; 2018 Oct; 97(10):2001-2003. PubMed ID: 29728736
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma.
Cencini E; Fabbri A; Schiattone L; Bocchia M
Leuk Lymphoma; 2019 Mar; 60(3):833-835. PubMed ID: 30234387
[No Abstract] [Full Text] [Related]
6. Hyperhemolysis associated with marginal zone lymphoma.
Yan M; Callum J; Lin Y
Leuk Lymphoma; 2015 Mar; 56(3):829-31. PubMed ID: 24991717
[No Abstract] [Full Text] [Related]
7. Cardiac Light Chain Deposition Disease Mimicking Immunoglobulin Light Chain Amyloidosis: Two Branches of the Same Tree.
Osanami A; Yano T; Takemura G; Ikeda H; Inyaku M; Toda Y; Kamiyama N; Sugawara H; Gocho Y; Fujito T; Nagano N; Takahashi S; Muranaka A; Tanaka M; Moniwa N; Murase K; Takada K; Kuroda H; Ogawa Y; Miura T
Circ Cardiovasc Imaging; 2020 Sep; 13(9):e010478. PubMed ID: 32873072
[No Abstract] [Full Text] [Related]
8. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
[No Abstract] [Full Text] [Related]
9. Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum.
Audard V; Georges B; Vanhille P; Toly C; Deroure B; Fakhouri F; Cuvelier R; Belenfant X; Surin B; Aucouturier P; Mougenot B; Ronco P
Clin J Am Soc Nephrol; 2008 Sep; 3(5):1339-49. PubMed ID: 18632851
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.
Castelli R; Bergamaschini L; Deliliers GL
Med Oncol; 2017 Dec; 35(2):15. PubMed ID: 29288421
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: preliminary data].
Logvinenko OA; Vasil'ev VI; Sedyshev SKh; Safonova TN; Rodionova EB; Kokosadze NV; Aleksandrova EN; Cherkasova MV; Radenska-Lopovok SG; Nasonov EL
Ter Arkh; 2012; 84(12):88-96. PubMed ID: 23479998
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Carter SJ; Bernstein SH; Friedberg JW; Barr PM
Leuk Res; 2011 Nov; 35(11):e223-4. PubMed ID: 21824654
[No Abstract] [Full Text] [Related]
13. Endobronchial mucosa-associated lymphoid tissue (MALT) lymphoma.
Yamasaki M; Funaishi K; Muta T; Matsumoto N; Taniwaki M; Hattori N
QJM; 2019 Oct; 112(10):807-808. PubMed ID: 30895318
[No Abstract] [Full Text] [Related]
14. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
16. Treatment of IgM-associated immunoglobulin light-chain amyloidosis with rituximab-bendamustine.
Manwani R; Sachchithanantham S; Mahmood S; Foard D; Sharpley F; Rezk T; Lane T; Quarta C; Fontana M; Lachmann HJ; Gillmore JD; Whelan C; Hawkins PN; Wechalekar AD
Blood; 2018 Aug; 132(7):761-764. PubMed ID: 29925500
[No Abstract] [Full Text] [Related]
17. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab.
Liu Z; Markham M; Mandernach MW
BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30872333
[TBL] [Abstract][Full Text] [Related]
18. Nodal marginal-zone lymphoma associated with monoclonal light-chain and heavy-chain deposition disease.
Went P; Ascani S; Strøm E; Brorson SH; Musso M; Zinzani PL; Falini B; Dirnhofer S; Pileri S
Lancet Oncol; 2004 Jun; 5(6):381-3. PubMed ID: 15172359
[No Abstract] [Full Text] [Related]
19. [Leg ulcer associated with type I cryoglobulinaemia due to incipient B-cell lymphoma].
Lacoste C; Duong TA; Dupuis J; Haioun C; Plonquet A; Copie-Bergman C; Gaulard P; Ortonne N
Ann Dermatol Venereol; 2013 May; 140(5):367-72. PubMed ID: 23663709
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin heavy chain can be amyloidogenic: morphologic characterization including immunoelectron microscopy.
Mai HL; Sheikh-Hamad D; Herrera GA; Gu X; Truong LD
Am J Surg Pathol; 2003 Apr; 27(4):541-5. PubMed ID: 12657941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
